entx

Webinar Episode #1

Company Overview
March 2026

About entX

entX is a nuclear science and advanced manufacturing company leading the advancement of innovative technologies, to create scalable technologies for the healthcare and Space and Defence sectors.

entX aims to deliver sovereign capabilities in breakthrough technologies, enhancing global security and value for shareholders with sustainable solutions united by radioisotope innovation across all pillars.

Space & Defence

ADVANCING RADIOISOTOPE POWER SYSTEM SOLUTIONS

IsoMedica

PIONEERING THE FUTURE OF MEDICAL ISOTOPES

Backed by $4.8 million in grants—our IsoMedica Facility is advancing toward a leadership position in a projected A$695 million market, with reduced development risk and growing national significance.

^{212}Pb

^{177}Lu

Pioneering Radioisotope Innovation

IsoMedica

Mines to medicine strategy, by leveraging mining and nuclear expertise to develop secure supply chains at scale for the radiopharmaceutical industry as it commercialises cancer drugs ~US$12bn TAM[1]

Mines to Medicine

- Leverages resources industry expertise to secure radioisotope supply chains
- Australia's first commercial radioisotope production facility under construction
- Established supply and offtake agreements with key partners
- Establishing a vertically integrated, sovereign Ra-226 supply chain by leveraging resources and energy sector expertise to secure Radium 226 - critical for scalable, long-term Pb-212 production and Ac-225.

Other Technologies

- PhosEnergy Process
- Carbon transition technologies
- Other commercialisation opportunities leveraging platform technologies and capabilities developed by entX.

Space and Defence

Positioned strategically to capitalise on US$1.3bn TAM[2] with GenX and RHU technologies for lunar and defence applications

GenX Betavoltaic Power Generator

- GenX is powered by beta-emitting radioisotopes that decay energy captured by a unique semiconductor device to produce continuous long-life electrical power.
- Disruptive IP sets new power density standards, supported by 5 patents
- Scalable low-cost volume manufacturing enables rapid global deployment

Radioisotope Heating Unit (RHU)



- Safe, low-cost radioisotope technology extends lunar mission life from weeks to up to four years
- Extending missions fundamentally improves the economics of lunar deployment
- Collaborating with multiple customers to engineer solutions for upcoming missions
- Leverages medical isotope supply chains bypassing constraints

1. Source: MarkNtel Advisors, Precedence Research
2. Source: researchandmarkets.com

Leadership Team

Management

Bryn Jones
Co-Founder
Managing Director

Leigh Whicker
Commercial Manager

Dr Julian Kelly
Co-Founder
Chief Technical Officer

Damien Connor
CFO & Company Secretary

Dr Massey de los Reyes
Principal Scientist IsoMedica

Dr Scott Edwards
General Manager – Space and Defence

Board of Directors

Tony Kiernan
LLB
Chairman

Bryn Jones
BAppSc, MMinEng, FAustMM
Managing Director

Lucy Gauvin
BCom (CorpFin), LLB
Non-Exec Director

Tim Wise
BSc
Non-Exec Director

Gabriel Liberatore
BSc (Hon), PhD, MBA
Non-Exec Director


IsoMedica

Global Radiopharmaceutical Industry

IsoMedica

SECTOR TAILWINDS

Top Radiopharmaceutical Companies

Telix AdvanCell AstraZeneca CLARITY PHARMACEUTICALS NOVARTIS

- +30 radiopharma companies with +200 drugs under various stages of development
- Leverage this significant investment by becoming a key supplier

The need to eliminate reliance on Russian isotope supply chains. FDA and TGA resilience requirements effectively prevent commercial drugs from depending on Russian precursors, requiring Western-sovereign Pb-212 supply.

Strong global growth trajectory in the radioisotope and radiopharmaceutical markets, driven by rising demand for precision cancer diagnostics and targeted therapies.

The radiopharmaceutical sector is increasingly reliant on the development of secure, reliable supply chains for critical precursor isotopes, particularly those sourced and processed in politically stable, well-regulated jurisdictions.

Development of Commercial Supply Chain

IsoMedica

Lead-212

Mining and Mineral Waste → Advanced Radiochemical Production Facility (ARPF) → Thorium-228 (Ultra High Purity)

- One of the few firms capable of owning and operating a commercial medical isotope production facility
- Leverages mining partnerships, Tellus Holdings waste streams, and novel Th-228 extraction process
- Late stages of commercialising LOIs with Telix and AdvanCell for Th-228 and Ra-226
- **TAM** estimated at **>AUD $300m**[1] p.a (Th-228)
- 20+ drugs under development, 7 in clinical trials

Thorium-228 (Ultra High Purity) → Sale to Lead-212 Producers (Telix, AdvanCell, Perspective Therapeutics, ARTBIO)

Thorium-228 (Ultra High Purity) → entX Lead-212 Production (non-clinical) → Sales to drug developers

IsoMedica

Lutetium-177

Natural Ytterbium (~12.5% Yb-176) → entX Isotope Purification → Yb-176 (>95% Yb-176)

- entX proprietary low-capex scalable isotope purification technology
- Produces higher purity Yb-176 (Lu-177 precursor) with high reactor compatibility
- 2 approved drugs, +200 under development, 17 in phase 3
- **TAM** estimated at **~A$700m** by 2030 p.a. (enriched Yb-176)

Yb-176 (>95% Yb-176) → ANSTO / Nuclear Reactors → End Users

1. Based on a current price of USD $135 / MBq of Throrium-228

IsoMedica Updates

IsoMedica

Market Trigger

Supply is the bottleneck to drug commercialisation. Pharma has committed billions with 200+ drugs in development with no western commercial supply chain.

Where we are Now

- Awarded AUD $1.9m ERF grant to build Australia's first commercial isotope production facility (ARPF)
- All key development and licensing approvals secured
- Construction Long-lead capital items ordered
- Transitioning from grant-funded development to customer contract revenue
- Engineering optimisation underway to support rapid scale-up from lab to manufacturing.

Upcoming Catalysts

- Installation and commissioning of major equipment (July)
- ARMF commissioning at Greenfields – first production targeted for Q4
- Finalisation of waste material offtake agreements with global mining partners
- Ongoing engagement with potential end users and collaborators
- Conversion to commercial supply contracts
- Provide Pb-212 radiolabeling services for drug developers along with Pb-212 isotope for trials.



Space and Defence

Space & Defence Focus Technologies

SECTOR TAILWINDS



Structural rearmament, not a cycle. Global defence budgets to exceed $2.6 trillion in 2026 creating durable demand for sovereign platform technologies.

Modern warfare runs on persistent, unattended sensing - power is the critical constraint. Military sensors market growing from $11B to $19B by 2034. Field-deployed sensors in remote and contested terrain can't be maintained - GenX delivers years of power with zero logistics tail.

The lunar economy is launching now - night survival is the #1 gap. 4+ commercial landers targeting the Moon in 2026 alone. NASA ranks lunar night survival its #1 technology gap. entX's RHU is the only commercial solution.

GenX – Improving Resilience in Space and Defence

GENX BETAVOLTAICS FOR LONG LASTING POWER





What	Applications Targeted	Commercial Traction	entX's Competitive Advantage
GenX is a nuclear battery - no charging, no maintenance, no moving parts. Continuous power for years or decades from a small, sealed device.	• Unattended ground sensors and remote IoT devices – priority near-term market with shorter qualification cycles • Spacecraft and cis-lunar platforms requiring maintenance free, long-duration power • Autonomous Underwater Vehicles (UUV) – GenX as persistent power with hybrid power packs, extending mission endurance beyond battery limits	• **Already exceeds DARPA's 2030 power density target**, the only technology to do so • Engaged specialist US defence advisor with direct access to key government programs and procurement pathways • Active engagement underway targeting unattended ground sensors • Expect to be producing prototypes for testing by mid-year	• Robust IP in electrode and semiconductor tech - 5 patents and US patent pending • First betavoltaic manufacturer to use industry-standard semiconductor processes enabling low-cost scale production

Radioisotope Heating Unit (RHU)

RHU FOR LUNAR NIGHT SURVIVAL



Civil Space Shortfall Ranking: Integrated List

Using the methodology described, the Civil Space Shortfall Ranking integrates inputs from NASA mission directorates and centers, small and large industry organizations, other government agencies, academia, and other interested individuals. The list is ranked from highest (1) to lowest (187).

The **bolded black text** in the table indicates the shortfall is within the top three ranked shortfalls in its capability category.

Integrated Rank	Average Integrated Score	Shortfall ID	Capability Category
1	8.1035	**1618: Survive and operate through the lunar night**	Thermal Management Systems
2	7.6118	**1596: High Power Energy Generation on Moon and Mars Surfaces**	Power
3	7.4345	**1554: High Performance Onboard Computing to Enable Increasingly Complex Operations**	Avionics

What

- Utilises safe, commercially available radioisotopes within proprietary RHU device design to heat critical systems for lunar night survival
- Extends mission life, eliminate heavy batteries, which adds to payload cost) and boost asset efficiency

Applications Targeted

- Small payloads and rovers – extends mission life from days to months surviving the two-week lunar night without heavy batterers
- Supports 2-5 year survival for semi-permanent lunar installations
- Spacecraft and platform thermal management – entX's proprietary TMS developed for RHU addresses a gap where no solution exists

Commercial Traction

- RHU launch scheduled later this year making it the first ever commercial RHU to achieve flight heritage
- LOI for up to 48 RHUs by 2030
- A$1m advanced supply agreement secured for first launch
- Proposal under evaluation for entX's TMS as a standalone capability
- Agreement with Japanese lander company, ispace.

entX's Competitive Advantage

- Only commercial RHU solution available - no comparable western product exists
- Proprietary TMS developed in-house fills a market gap
- Leverages medical isotope supply chains bypassing constraints
- Extending missions materially improves the economics of lunar deployment

Space and Defence Updates

Market Trigger

Sensors, autonomous systems and lunar platforms are all hitting the same wall: batteries run out and you can't send someone to charge them. GenX and RHU solves this.

Where we are Now

- CRC-P and Moon to Mars Trailblazer programs nearing completion with successful outcomes
- $1.8M partnership with AMCRC and Adelaide University
- 14-month validation and in-house manufacturing scale-up program underway
- Transitioning GenX from prototype to pre-commercial manufacture
- Ongoing collaborative partnerships with end users with high commercial potential.

Upcoming Catalysts

- RHU Flight Heritage launch in New Mexico (later this year)
- Commissioning of Space Defence Manufacturing at Greenfields
- Systems integration pathway with ispace and Fleet Space for future lunar missions
- Advancement toward mission-ready, integrated systems
- Progression to recurring commercial contracts.

What's Next?

WEBINAR SERIES

- Learn more about our Nuclear Medicine technology with IsoMedica
- Deep dive into our GenX Technology
- Live Q&A sessions with technical experts and leadership team
- Behind-the-scenes look at entX's certified radiation facility





Thank you for your time.
Any questions?

Bryn Jones
Founder and Managing Director

entX Limited
https://www.entx.com.au

Follow us @entxlimited